What is Sun Pharma's interest in Organon?

Sun Pharma has submitted a non-binding offer to acquire Organon, aiming for a significant global expansion.

How is Sun Pharma financing the potential Organon acquisition?

The potential acquisition is backed by bridge loans totaling $10-14 billion from several global banks.

What is Organon's strategic focus?

Organon is divesting certain businesses to focus on its women's health biopharma range, particularly products like Nexplanon.

Home / Business and Economy / Sun Pharma Eyes Organon in $10-14B Mega-Deal

Sun Pharma Eyes Organon in $10-14B Mega-Deal

20 Jan

•

Summary

Sun Pharma submitted a non-binding offer to acquire Organon.
The deal is financed with $10-14 billion in bridge loans.
Organon is focusing on biopharma while divesting devices.

Sun Pharma Eyes Organon in $10-14B Mega-Deal

Sun Pharmaceutical Industries Ltd. has submitted a non-binding offer to acquire US-headquartered Organon, marking its most ambitious global expansion. The company has secured acquisition financing through bridge loans from international banks, ranging from $10 to $14 billion, demonstrating its commitment. Following this initial bid, a due diligence process is expected to commence shortly, paving the way for a potential binding offer.

This move intensifies Sun Pharma's pursuit of Organon, a company that recently divested its JADA post-partum haemorrhage treatment system to focus on its women's health biopharma offerings, including its top-selling product Nexplanon. Organon, spun off from Merck Sharp & Dohme in 2021, has been seeking to divest businesses amidst existing debt and a strategic pivot.